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Background: Tamoxifen resistance is a major problem in the treatment of estrogen receptor (ER) α -positive breast
cancer patients. Although the mechanisms behind tamoxifen resistance are still not completely understood, clinical
data suggests that increased expression of receptor tyrosine kinases is involved. Here, we studied the estrogen and
anti-estrogen sensitivity of human breast cancer MCF7 cells that have a moderate, retroviral-mediated, ectopic
expression of epidermal growth factor receptor (MCF7-EGFR).
Methods: Proliferation of MCF7-EGFR and parental cells was induced by 17β-estradiol (E2), epidermal growth factor (EGF)
or a combination of these. Inhibition of proliferation under these conditions was investigated with 4-hydroxy-tamoxifen
(TAM) or fulvestrant at 10−12 to 10−6 M. Cells were lysed at different time points to determine the phosphorylation status
of EGFR, MAPK1/3, AKT and the expression of ERα. Knockdown of target genes was established using smartpool siRNAs.
Transcriptomics analysis was done 6 hr after stimulation with growth factors using Affymetrix HG-U133 PM array plates.
Results: While proliferation of parental MCF7 cells could only be induced by E2, proliferation of MCF7-EGFR
cells could be induced by either E2 or EGF. Treatment with TAM or fulvestrant did significantly inhibit proliferation
of MCF7-EGFR cells stimulated with E2 alone. EGF treatment of E2/TAM treated cells led to a marked cell proliferation
thereby overruling the anti-estrogen-mediated inhibition of cell proliferation. Under these conditions, TAM however
did still inhibit ERα- mediated transcription. While siRNA-mediated knock-down of EGFR inhibited the EGF- driven
proliferation under TAM/E2/EGF condition, knock down of ERα did not. The TAM resistant cell proliferation mediated
by the conditional EGFR-signaling may be dependent on the PI3K/Akt pathway but not the MEK/MAPK pathway,
since a MEK inhibitor (U0126), did not block the proliferation. Transcriptomic analysis under the various E2/TAM/EGF
conditions revealed that E2 and EGF dependent transcription have little overlap and rather operate in a parallel fashion.
Conclusions: Our data indicate that enhanced EGFR-driven signalling is sufficient to overrule the TAM- mediated
inhibition of E2-driven cell proliferation. This may have profound implications for the anti-estrogen treatment of
ER-positive breast cancers that have increased levels of EGFR.
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Breast cancer is the most common cancer among women
worldwide. Despite the improvement in treatment, therapy
resistance remains a major problem in the clinic. Endocrine
therapy has become the most important treatment option
for women with estrogen receptor (ER) α -positive breast
cancer, which is approximately 70% of all breast tumours.
The ERα − antagonist tamoxifen is commonly used
with these ERα-positive breast cancers. Unfortunately,
around 40% of all ERα-positive patients do not respond to
tamoxifen treatment (de novo resistance) [1]. Furthermore,
most patients that initially respond to tamoxifen treatment
eventually develop resistance (acquired resistance) [2,3].
Clinical data indicate that tamoxifen resistant breast
cancers often have an increased expression of the receptor
tyrosine kinase (RTK) epidermal growth factor (EGF)
receptor (EGFR/ERBB1) and its family member ERBB2
[1,4,5]. Also increased activation of their downstream
target mitogen activated protein kinase (MAPK) leading
to increased phosphorylation of the estrogen receptor on
serine 118 or serine 167, have been found [6-8]. Because
MAPK can be activated downstream from EGFR and/or
ERBB2 and may phosphorylate the ERα at serine 118,
together these observations suggest that the EGFR/
ERBB2 signalling pathways might play a role in tamoxifen
resistance.
The above clinical findings are confirmed by several
in vitro studies which show that continuous culturing of
the human breast cancer cell line MCF7 in the presence
of the anti- estrogen tamoxifen or fulvestrant increases
EGFR and ERBB2 expression and the activation of
downstream signalling kinases (e.g. MAPK) [9-11]. This
is in contrast to another study in which no change in
the EGFR/ERBB2 signalling pathway upon long term
tamoxifen treatment is observed [12]. Nevertheless, in
the latter study an increased MAPK phosphorylation upon
tamoxifen stimulation and an enhanced ERα-EGFR
interaction were observed [12]. In all studies the
antagonistic effect of tamoxifen could be restored by
co- treatment with tyrosine kinase inhibitors against
either the EGFR or against MAPK and PI3K/Akt
[9-13]. Even more evidence for a role of EGFR and
ERBB2 in tamoxifen resistance comes from in vivo
experiments in mice. Masserweh et al. showed that
EGFR and ERBB2 expression was markedly increased
when MCF-7 xenograft tumours became tamoxifen resist-
ant compared to control estrogen-treated tumours [14].
Together these observations suggest that the EGFR/
ERBB2 signalling pathways might play a role in tamoxifen
resistance.
Several in vitro studies show down regulation of ERα
due to signalling by highly over expressed EGFR/ERBB2
pathway components [1,15-17], resulting in de novo or
acquired tamoxifen resistance. Also in clinical studies, aninverse correlation between EGFR and ERα expression in
tamoxifen resistant patients has been reported [5,6,18-20].
However, expression of both ERα and EGFR was observed
in at least 50% of the patients [20]. Furthermore, in a meta
analysis involving >5000 patients, EGFR positivity was
observed in 4-51% (mean 29%) of ERα-positive tumors
and in 29-91% (mean 59%) of ERα-negative tumors [21].
No correlations with tamoxifen were reported. In addition,
several in vitro studies showed no down regulation of the
ERα in cell lines that were long-term cultured in the
presence of tamoxifen [9,10,22]. Thus, it appears that high
expression of EGFR may down regulate ERα, while more
moderate levels of EGFR are found in ERα-positive
tumors. In this paper we focus on the latter situation
and have investigated the mechanisms responsible for
anti-estrogen resistance in this situation.
Despite all research done, the mechanism by which over
expression of receptor tyrosine kinases induce anti-estrogen
resistance is still unclear. For instance, some studies suggest
that increased EGFR signalling itself induces anti-estrogen
resistance [23-26], while in contrast others suggest that
increased crosstalk between ERα and RTKs might be
responsible [12,14,22,27-30]. Furthermore, other data
also suggest a role for ERα phosphorylation by RTK
downstream signalling, in anti-estrogen resistance
[9,31-34]. The diversity of the explanations for the effect
of RTKs on tamoxifen resistance may suggest a very
complex mechanism behind the anti-estrogen resistance.
Typically, these above mentioned studies are performed in
anti-estrogen resistant breast tumour cell models that are
created by long term culturing of human breast cancer
cells in the presence of different anti- estrogens. This
allows adaptation of the cells to reduced pro-mitogenic
signals and may result in selection of cells with increased
levels and/or activation of EGFR/ERBB2 [9,10,22,26].
However, other cellular programs may have changed
in these anti-estrogen resistant cells as well which
also may contribute to acquired tamoxifen resistance.
Therefore, studies using isolated EGFR expression are
required.
In this study we created human breast cancer MCF7
cells that ectopically express human EGFR (MCF7-EGFR)
with a 3-fold induction compared to wild type MCF7 cells,
allowing the study of EGFR exclusively in the context of
anti-estrogen activity of tamoxifen. Importantly, in these
cells EGFR activity is low under basal conditions, but
is greatly enhanced by EGF treatment. This enhanced
signalling leads to loss of anti-proliferative effect of
tamoxifen. In contrast, classic genomic ERα signalling
remains anti-estrogen sensitive. Genome-wide tran-
scriptomic analysis showed the existence of specific
E2 and EGF induced transcriptional programs that do
not significantly overlap and operate in a parallel
fashion.
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moderate EGFR expression would also be intrinsic re-
sistant to anti-estrogens. First line combined therapy of
ER/EGFR positive breast cancer with EGFR inhibitors
and tamoxifen would therefore be more effective.
Methods
Materials
Antibodies against ERα (sc-543), and EGFR (sc-03) were
from Santa Cruz Biotechnology (Heidelberg, Germany);
antibodies against phosphorylated Akt (9271S), mitogen
activated protein kinase 42–44 (MAPK) and phosphorylated
MAPK (9101 and 137 F5), and phosphorylated EGFR
(4407) were from Cell Signalling Technologies (Leiden, The
Netherlands); antibody for Akt was a kind gift from P.
Coffer (UMC, Utrecht, The Netherlands). For analyzing
phosphorylated proteins the Western-Star immunodetection
kit (Tropix kit) from Applied Biossytems (Foster City, CA,
USA) was used. TAM, fulvestrant, E2, EGF, and the protein
dye sulforhodamin B (SRB) were from Sigma Aldrich (St
Louis, MO, USA). Mitogen-activated kinase kinase (MEK)
inhibitor U0126 (V-112A) was from Promega (Leiden, The
Netherlands); Phosphoinositide 3-kinase (PI3K) inhibitor
BEZ235 (S1009) was from Selleck (Houston, TX, USA).
Cell culture
All cells were cultured in RPMI 1640 medium (Gibco, Life
Technologies, Grand Island, NY, USA) supplemented with
10% fetal bovine serum (FBS) and penicillin/streptomycin
(25 Units/mL each) at 37°C and 5% carbon dioxide. For es-
trogen deprivation, cells were cultured for 48 hrs in starva-
tion medium consisting of phenol red free RPMI 1640
medium (Gibco) supplemented with 5% charcoal dextran
treated fetal bovine serum (CDFBS) (HyClone, Thermo Sci-
entific, Waltham, MA, USA) and penicillin/streptomycin.
Establishment of MCF EGFR cells
Retroviral transduction of MCF7 cells with a pMSCV-
blast-hEGFR retroviral vector, kindly provided by Dr. E.
Danen (Leiden Academic Centre for Drug Research, The
Netherlands) [35], followed by blasticidin selection
(12.5 μg/ml) was used to generate MCF7-hEGFR cells.
After 7 passages of continuous selection with blasticidin,
EGFR transduced cells were harvested by fluorescence-
activated cell sorting (FACS). Cells were maintained at
10 μg/ml blasticidin.
Proliferation assay
Parental MCF7 and MCF7-EGFR cells were plated in
96- wells plates (Costar, Fisher Scientific, Waltham, MA,
USA) at a density of 10.000 cells/well and allowed to at-
tach overnight and maintained in starvation medium
for 48 hrs. Subsequently, growth factors were added
(E2, EGF, TAM, etc.) and cells were allowed toproliferate for 5 days. The cells were fixed and stained
using the colorimetric sulforhodamin B (SRB) assay [36].
In short, cells were fixed with trichloroacetic acid at 4°C
for 1 hour, washed five times with tap water and air-dried.
Next, the cells were stained with SRB in 1% acetic acid at
room temperature for 30 min. Plates were washed five
times with 1% acetic acid and air-dried overnight.
Bound SRB was solubilised with 100 μL 10 mM aque-
ous unbuffered Tris solution (pH > 10) and absorbance
was measured at 540 nm. All data represent the average ±
SEM of three independent experiments each performed
with triplicate wells.
In a control experiment (Additional file 1: Figure S1),
cell proliferation was determined by staining cellular DNA
in 96-well tissue cultures plates with bisbenzimidazole
(Hoechst 33258) as described [37]. Briefly, the plates were
emptied of media and stored frozen. Subsequently 100 μL
distilled water was added to each well and frozen again.
Thereafter, they were stained with Hoechst 33258 in
5 mM Tris, 0.5 mM EDTA, 1 M NaCl pH 7.4. The assay
yielded a linear standard curve for DNA fluorescence ver-
sus cell number in a range appropriate for our experiment.
Immunoblotting
Estrogen depleted parental MCF7 and MCF7-EGFR cells
plated in 60-mm dishes were treated with different stimuli
after a 2 hr serum starvation period. After stimulation, cells
were placed on ice and washed twice with ice-cold PBS and
once with ice cold TSE (10 mM Tris, 250 mM Sucrose, and
1 mM EGTA). Next, cells were lysed in 60 μL TSE plus
inhibitors (1 mM DTT, 10 μg/mL leupeptin, 10 μg/mL
aprotinin, 1 mM vanadate, 50 mM sodium fluoride, 1 mM
PMSF) and lysates were placed in cold 1 mL eppendorf
tubes. After pulse sonication samples were stored at −20°C
until electrophoresis. Proteins were separated by electro-
phoresis (7.5% acrylamide gel) followed by transfer to PVDF
membrane (Millipore, Billerica, MA, USA). After blocking
with 5% bovine serum albumin (BSA) (Invitrogen, Grand
Island, NY, USA) and primary and secondary antibody
staining, protein bands were visualized by scanning the
membrane on a Typhoon 9400 (GE Healthcare, Fairfield,
CT, USA).
Immunofluorescent microscopy
Parental MCF7 and MCF7-EGFR cells plated on glass cov-
erslips were fixed with 4% formaldehyde for 10 min at
room temperature, washed three times with PBS and then
blocked with TBP (10% Triton, 1% BSA in PBS pH 7.4) for
1 hour at room temperature. Primary antibodies diluted in
TBP were added for incubation overnight at 4°C. There-
after, secondary antibody conjugated with Alexa488 was
added together with Hoechst33258 (2 μg/ml) for 30 min
at room temperature in the dark and post-fixated with 4%
formaldehyde for 5 min. After washing with TBP and PBS,
Moerkens et al. BMC Cancer 2014, 14:283 Page 4 of 15
http://www.biomedcentral.com/1471-2407/14/283coverslips were mounted on a glass slide using Aqua-
Poly/Mount (Polysciences Inc., Warrington, PA, USA).Small interfering RNA (siRNA)-based knockdown
Knockdown of target genes was established by a reverse
transfection using smartpool siRNAs according to the
manufacture’s protocol (Dharmacon, Pittsburgh, PA,
USA) using Dharmafect 4 reagent and with final siRNA
concentration of 50 nM.Luciferase reporter assays
Parental MCF7 and MCF7-EGFR cells were plated at a
density of 40.000 cells/well in a 48- wells plate in culture
medium without antibiotics. The next day cells were trans-
fected with 0.16 μg ERE-tk-luciferase plasmid (kind gift of R.
Michalides, Netherlands Cancer Institute, Amsterdam)
using Lipofectamine Plus reagents (Invitrogen) according to
manufacturer’s protocol. After 3 hours incubation medium
was replaced with starvation medium. Cells were cultured
for 48 hrs before treatment with different compounds. The
medium was discarded after 12 hrs and cells were washed
once with PBS and then lysed with 1x passive lysis buffer,
from the Dual-Luciferase kit (Promega, Madison, WI, USA).
Luciferase activity was measured using the Dual- Luciferase
kit (Promega, Madison, WI, USA) on a luminometer
(CentroXS3 LB960, Berthold Technologies, Bad Wildbad
Germany).Transcriptomics analysis
For microarray analysis of gene expression, MCF7-EGFR
cells were seeded at 60% confluence in 6-cm plates and
subjected to three-day starvation in 5% charcoal/dex-
tran- stripped fetal bovine serum medium prior to treat-
ments with TAM (10 μM), E2 (10 nM) and EGF
(100 ng/mL) in triplicate. After 6 hours, total RNA was
extracted using a RNA isolation kit (Ambion, Inc., Aus-
tin, TX, USA). Affymetrix 3′ IVT Express Kit (Affymetrix,
Santa Clara, CA, USA) was used to synthesize biotin-
labeled cRNA, and this was hybridized to a Affymetrix HG-
U133 PM Array plate. Raw expression data were obtained
by probe summarization and background correction
according to the robust multiarray averaging method
[38]. Median normalization of raw expression data and
identification of differentially expressed genes using a
random variance t-test was performed using BRB-
ArrayTools [39] version 4.1.0 Beta 2 Release (developed
by Dr. Richard Simon and BRBArrayTools Develop-
ment Team members). Corrections for multiple testing
were made by calculating the false discovery rates ac-
cording to Benjamini & Hochberg [40]. Affymetrix pro-
besets were annotated with Netaffx Annotation build
30 (dated 08-20-2010).Statistical analysis
Student’s t-test was used to determine if there was a
significant difference between two conditions/treatments
(p < 0.05). Significant differences are indicated in the figures.
Results
EGFR over expression in MCF7 cells enhances
downstream MAPK and Akt signalling
To investigate the role of EGFR on anti-estrogen resistance,
we established ectopic human EGFR expression in human
MCF7 breast cancer cells. Immunofluorescent staining of
these MCF7-EGFR cells showed an intense plasma-
membrane EGFR staining (Figure 1A) in contrast to the
parental MCF7 cells. Furthermore, FACS analysis also
demonstrated a clear increase of EGFR expression in the
established MCF7-EGFR cell line (Figure 1B). Next, we
determined the functionality of ectopically expressed
EGFR by analyzing the downstream signalling upon EGF
stimulation. Cells were serum starved for 2 hours prior to
EGF stimulation (100 ng/mL). The MCF7-EGFR cells
showed a long lasting (>120 min) increased phosphoryl-
ation of the EGFR upon EGF stimulation (Figure 1C). This
EGFR activation was associated with enhanced activation
of the downstream kinases MAPK1/3 and Akt (Figure 1C).
Importantly, no difference in ERα protein expression
between the two cell lines was observed at 2 hr (Figure 1C),
2 days and 5 days after continuous EGF stimulation
(Additional file 2: Figure S2), indicating that this level of
EGFR expression does not affect ERα levels.
MCF7-EGFR proliferation can be induced by both
estrogen and EGF
Both MCF7 parental and MCF7-EGFR cells showed a clear
estrogen-dependent increase in proliferation (Figure 2A).
However, stimulation with EGF induced proliferation of
only the MCF7-EGFR cells, which was almost the same as
E2-induced proliferation (Figure 2A). Furthermore, the
E2- induced proliferation did not increase by additional
EGF stimulation (Figure 2A), indicating lack of synergy
between EGF and E2 at the concentrations used.
We also investigated non-genomic effects of ERα
signalling by analyzing phosphorylation of MAPK1/3
after E2 stimulation (10 nM) in estrogen (48 hrs) and
serum (2 hrs) starved cells. The parental MCF7 and
MCF7-EGFR cells showed a small increase (1.5 and 2
fold respectively) in MAPK1/3 activation 30 seconds after
E2 stimulation (Figure 2B). However, this was much
smaller than the 5 and 35 fold increase by EGF
stimulation. Even when the estrogen stimulation was
prolonged, MAPK1/3 activation did not further in-
crease (data not shown). These results may suggest
that non-genomic effects of ERα in relation to
MAPK signalling might not be very important in
MCF7-EGFR cells.
Figure 1 Retroviral-induced EGFR over expression in MCF7 human breast cancer cells enhances downstream signalling. EGFR expression
was determined in parental MCF7 and MCF7-EGFR cells by immunofluorescence (A) and FACS analysis (B). To determine downstream EGFR signalling,
starved MCF7 parental and MCF7-EGFR cells were stimulated with EGF (100 ng/mL). Cell lysates were collected and analyzed by western blot for the
phosphorylation status of EGFR, MAPK1/3 and Akt as well as the expression of ERα (C).
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anti-estrogen tamoxifen
Next, we determined the effect of EGFR over expression
on the sensitivity towards the anti-estrogen tamoxifen.
Cells were estrogen-depleted for 48 hrs and then
exposed to a concentration series of TAM plus a fixed con-
centration E2 (0.1 nM) with or without EGF (100 ng/mL).
After 5 days, proliferation was determined. As expected,
TAM treatment resulted in a dose-dependent inhibition of
proliferation of parental MCF7 cells (Figure 3A). The
MCF7-EGFR cells without EGF showed a similar dose-
dependent inhibition of proliferation upon TAM treatment.
However, when the EGFR is activated by EGF exposure,
the MCF7-EGFR cells were no longer sensitive to
TAM. As the SRB assay that we used for determining
cell proliferation is based on measuring total cell pro-
teins, any change in cellular protein content by EGF
exposure may have influenced our results. Therefore,
we performed an independent experiment where we
determined cell proliferation by measuring total cellu-
lar DNA (see Methods). The results are in agreement
with the SRB assay and confirm that MCF7-EGFR
cells after EGF exposure are no longer sensitive to
TAM (Additional file 1: Figure S1).Subsequently, we tested whether the EGF-mediated
protection against TAM was dependent on the EGFR sig-
nalling. For this purpose we performed siRNA-based knock-
down of EGFR in both the MCF7 and MCF7-EGFR cells.
After a starvation period of 48 hrs, cells were stimulated
with either E2 (0.1 nM), EGF (100 ng/mL), E2 and EGF, or
E2 plus EGF and TAM (100 nM). Western blot analysis
showed a 60% knock down of EGFR compared to control
GFP siRNA, which led to decreased activation of the down-
stream kinases MAPK1/3 and Akt upon EGF stimulation in
both MCF7 parental and MCF7-EGFR cells (Figure 4A).
Furthermore, as expected, EGF-induced proliferation of
MCF7-EGFR cells decreased significantly in cells with a
knock down of EGFR compared to cells with a control
siRNA (Figure 4B). Knock down of EGFR in the MCF7-
EGFR cells resulted in almost complete re- sensitization
towards TAM treatment (Figure 4B). This indicates that the
EGFR signalling pathway is dominant over the TAM-
induced inhibition of estrogen-driven proliferation.
MCF- EGFR cells show resistance to the anti-estrogen
fulvestrant
Next, we determined the sensitivity of the MCF7-EGFR
cells towards another clinically relevant anti-estrogen,
Figure 2 EGFR over expression does not influence estrogen-dependent proliferation. To investigate the proliferation induced by either
estrogen or EGF both, parental MCF7 and MCF7-EGFR cells, were cultured in phenol red free medium with 5% charcoal treated serum for
48 hours, followed by an exposure to 0.1 nM E2, 100 ng/mL EGF or a combined exposure. The control cells were exposed to DMSO only. Cells
were left to proliferate for 5 days and then fixed with 50% trichloroacid (TCA). Fixed cells were stained with sulforhodamin B, which absorption
was measured at 540 nm (A). Graphs represents the average relative proliferation ± SEM of three independent experiments, * indicates significant
difference of p < 0.05. To determine the role for the fast non-genomic effects of ERα, starved MCF7 parental and MCF7-EGFR cells were exposed to 10 nM
E2 for the indicated times before lysates were collected and analyzed by western blot for the phosphorylation status of MAPK1/3 (B). – and + indicate
negative control (DMSO) and positive control (EGF, 100 ng/mL).
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binds, blocks and degrades the ERα [41]. Therefore, all
ERα-dependent pathways are expected to be inhibited
by fulvestrant. Cells were estrogen-depleted for
48 hrs and then exposed to a concentration series of
fulvestrant plus a fixed concentration E2 (0.1 nM)
with or without EGF (100 ng/mL). The MCF7 paren-
tal cells showed an almost complete, dose-dependent
inhibition of proliferation by fulvestrant that was
independent of EGF treatment (Figure 3B). This is similar
to the effect of TAM.
Treatment of the MCF7-EGFR cells with fulvestrant
resulted in a dose-dependent inhibition of proliferation
as well (Figure 3B). However, co-treatment of these cells
with EGF decreased the inhibitory effect of fulvestrant,
similar to the effect on TAM.Knock down of ERα blocks E2- but not EGF-induced
proliferation
To determine whether EGF-induced EGFR signalling
resulting in tamoxifen resistance involves ERα or not,
we introduced a siRNA targeting ERα in both parental
MCF7 and MCF7-EGFR cells, which resulted in 70% ERα
knock down (Figure 4C). This ERα knockdown did not
decrease the activation of MAPK1/3 or Akt upon EGF
stimulation (Figure 4C). However, estrogen-induced
proliferation was greatly reduced in ERα knockdown
cells compared to control GFP siRNA (Figure 4D),
although some E2-driven proliferation was still observed,
possibly related to residual ERα protein levels due to no
full ERα knockdown. EGF-induced proliferation was not
significantly affected by ERα knockdown in neither
MCF7 parental nor MCF7-EGFR cells. These results
Figure 3 EGFR over expression induces tamoxifen and fulvestrant resistance. Parental MCF7 and MCF7-EGFR cells were estrogen starved
48 hours prior to a 5 day proliferation period in the presence of 0.1 nM E2 with a concentration series TAM (A) or fulvestrant (B), with or without
100 ng/mL EGF. Afterwards, cells were fixed with 50% TCA and stained with sulforhodamin B, which absorbance was measured at 540 nm. Graphs
represent the average ± SEM of three independent experiments.
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proliferation in the absence of ERα in MCF7-EGFR cells.
MEK/MAPK pathway is not responsible for EGFR-mediated
proliferation and tamoxifen “resistance” of MCF7-EGFR cells
To determine the downstream signalling that defines the
EGFR-mediated proliferation and resistance to tamoxifen
we treated our cells with an inhibitor of MEK1/2 (U0126,
10 μM) and an inhibitor of PI3K (BEZ235, 1 μM) and
measured the proliferation of MCF7 parental and
MCF7-EGFR cells treated with E2 (0.1 nM), EGF
(100 ng/mL), E2 and EGF, or E2 plus EGF and TAM
(100 nM). Western blot analysis showed reduced
MAPK1/3 activation upon U0126 treatment and reduced
Akt activation upon BEZ235 treatment in both parental
MCF7 and MCF7-EGFR cells (Figure 5A). Treatment with
the MEK1/2 inhibitor resulted in decreased proliferation of
serum starved MCF7 parental as well as MCF7-EGFR
cells compared to control (Figure 5B). Similarly, prolifera-
tion after E2, EGF, E2 + EGF, and E2 + EGF +TAM stimu-
lation was decreased as well compared to control
(Figure 5B). The decrease in proliferation, however, was
comparable to the decrease in proliferation in the
starvation conditions. The MEK1/2 inhibitor did not changethe effect of TAM on proliferation of parental MCF7
and MCF7-EGFR cells in the presence of E2 and EGF
(Figure 5B). These results suggest that the MEK/MAPK
pathway is not responsible for the apparent tamoxifen
resistance in MCF7-EGFR cells. Treatment with the PI3K
inhibitor BEZ235 almost completely blocked proliferation
induced by E2, EGF, or by a combination of the two
(Figure 5C) in parental MCF7 and MCF7-EGFR cells.
BEZ235 also has an effect on starved control cells, which is
likely related to remaining background PI3K signalling
activity mediated by cell adhesion signalling and/or
autocrine responses. Yet, altogether our data indicate that
tamoxifen resistant cell proliferation mediated by the
conditional EGFR- signalling may be dependent on the
PI3K/Akt pathway but not the MEK/MAPK pathway, since
strong Akt activation is observed after EGF stimulation of
MCF7-EGFR cells (Figure 1C) and a MEK inhibitor
(U0126), did not block the proliferation.
Overexpression of EGFR does not overcome tamoxifen
inhibition on transcriptional level
Tamoxifen resistance may be related to altered regulation
of ERα-mediated transcriptional activity [14,22]. Therefore,
we investigated the effect of ectopic EGFR expression and
Figure 4 Knock down of EGFR reverses tamoxifen resistance of MCF7-EGFR cells and is ERα independent. EGFR (A) and ERα (C) knockdown in
MCF7 parental and MCF7-EGFR cells was established using siRNA. Knock down efficiency and the effect of EGFR knock down on phosphorylation status
of MAPK1/3 and Akt after 30 min EGF (100 ng/mL) exposure was analysed on western blot. GFP siRNA was used as control. (A, C) After
48 hours starvation knock down cells were exposed to 0.1 nM E2 plus 100 nM TAM and 100 ng/mL EGF. Proliferation was measured after
5 days using sulforhodamin B absorbance at 540 nm (B, D). Graphs represent the average ± SEM of three (A, B) or four (C, D) individual experiments,
* indicates significantly different at p < 0.05; # indicates significantly different at p < 0.01.
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MCF7-EGFR cells were transiently transfected with
an ERE-tk-luciferase construct. Estrogen induced
ERE-luciferase activity in both parental MCF7 andMCF7-EGFR cells 4-fold which could be inhibited by
tamoxifen (Additional file 3: Figure S3). Importantly,
TAM inhibited E2 induced ERE-luciferase activity also
after EGF stimulation in both parental MCF7 and
Figure 5 MCF7-EGFR tamoxifen resistance involves PI3K/Akt pathway. Parental MCF7 and MCF7-EGFR cells were starved for 48 hrs before
pre-treatment with either the MEK inhibitor U0126 (10 μM) or the PI3K inhibitor BEZ235 (1 μM) for 30 min. The effect of inhibition on EGF-induced
activation of MAPK1/3 and Akt was analyzed on western blot (A). Following U0126 and BEZ235 pre-treatment cells were exposed to 0.1 nM
E2, 100 nM TAM and 100 ng/mL EGF. Proliferation was measured after 5 days using sulforhodamin B absorbance at 540 nm (B, C). Graphs represent
the average ± SEM of three independent experiments, * indicates significant difference of p < 0.05, # indicates significant difference of p < 0.01.
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not block the inhibitory effect of tamoxifen on ERα
transcription activation by E2, as opposed to the effect on
proliferation. Furthermore, EGF stimulation itself did not
induce ERE-luciferase expression in MCF7 parental nor
MCF7-EGFR cells (Additional file 3: Figure S3 A and B)
indicating no important cross-talk between ERα and
EGFR signalling pathways at the transcriptional level.
Ensuing microarray gene expression analysis supported
these reporter assay results (see below). In addition, we
also measured ERE-luciferase expression at various times
(2–12 hrs) after stimulation of parental MCF7 and
MCF7 EGFR cells by EGF, with and without TAM,and these experiments also showed only little effect
of EGFR signalling on transcription compared to E2,
and no reinforcement of TAM on EGFR signalling
(Additional file 4: Figure S4).
Overexpression of EGFR does not induce agonistic effects
of tamoxifen
It has been suggested that ERα phosphorylation by RTK
downstream signalling, may alter it in such a way
that tamoxifen functions as an agonst [9,33,42,43].
We therefore investigated whether enhanced EGFR
signalling in our MCF7-EGFR cells led to agonistic
effects of tamoxifen on MCF7 and MCF7-EGFR cell
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effects of TAM after EGF stimulation on cell proliferation
(Additional file 5: Figure S5), or luciferase expression
(Additional file 4: Figure S4).
Microarray gene expression analysis of E2 and EGF
induced genes
Transcription analysis was performed to investigate the
degree of similarity of E2 and EGF activated signalling
pathways. E2 increased the expression of 897 genes by
1.5 fold in MCF7- EGFR cells after 6 hr, while a similar
number of genes was 1.5 fold lower expressed compared
to controls (Figure 6A). The number of genes induced
or decreased by EGF was slightly higher (1300). As
expected, TAM greatly reduced the number of genes 1.5
fold up- or down-regulated by E2. TAM hardly affected
the number of EGF regulated genes. TAM, however, had
a significant effect on the number of genes regulated by
combined E2 + EGF exposure due to down regulation of
E2 responsive genes (Figure 6B).
In order to further characterize the inhibitory effect of
TAM on E2 regulated genes, we calculated the percentage
of inhibition by TAM for each gene. The inhibition by
TAM of E2 induced genes was large: the expression of
more than 65% of E2 up regulated genes was inhibited by
TAM by >50% (Figure 6B). Interestingly, the effect of
TAM on genes up regulated by E2 under the condition of
combined E2 + EGF exposure (60% inhibition >50%) was
almost as big as with exposure to E2 alone. This indicates
that the inhibitory effect of TAM is only slightly affected
by exposure of the cells to EGF.
In general, similar observations were made for the
inhibitory effect of TAM on E2 down regulated genes
as for E2 up regulated genes (Figure 6C).
Further analysis of the E2 and EGF regulated genes
showed that the identity of E2 and EGF induced genes
are different: most genes up regulated by E2 (80%) are not
induced by EGF (Figure 7). Many known E2 regulated
genes such as TFF1, PGR, GREB1 and MYC belong to this
class. Similarly, the majority of EGF induced genes (86%)
is not induced by E2. However, there is number of genes
(170) that is up regulated >1.5 fold by both E2 and EGF,
and for part of these (68), there is a synergistic effect of E2
and EGF (Additional file 6: Table S1). Analysis with
Metacore software (Genego, St. Joseph, MI, USA)
suggests that the most important transcription factors for
these genes are AR, c-JUN, c-MYC, EGR1, ESR1,
HIF1A, p53 and SP1 (Additional file 6: Table S1),
which is consistent with the cell proliferation pathways
activated by E2 and EGF (see below).
Furthermore, there is a relatively large number of
genes (609) induced by combined E2 + EGF exposure
that is not induced by E2 or EGF alone. This most
likely is also due to a synergistic effect of E2 andEGF because 60% of these genes are already induced
by E2 or EGF alone but just below the threshold of
1.5 fold (between 1.2 and 1.5 fold).
Conversely, there is also an antagonistic effect because
some of the E2 up regulated genes are down regulated
by EGF, and visa versa (Additional file 7: Table S2). In
conclusion, the majority of genes are uniquely induced
by either E2 or EGF and only for a limited number
of genes there is an agonistic or antagonistic effect.
Similar conclusions can be drawn for E2 and EGF down
regulated genes.
E2 and EGF induced cell signalling responsible for cell
proliferation
E2 and EGF induced expression of genes known to be
involved in the control of cell proliferation, and these were
different for E2 and EGF induced genes (Additional file 8:
Table S3). Thus, an important part of the E2 induced
signalling centres around activation of RB1-E2F pathway
that regulates the progression through the G1 phase of the
mammalian cell cycle [44]. This involves phosphorylation
of RB1 by the CyclinD/CdK4/6 complex. Factors activating
the CyclinD/CdK4/6 complex include CDC25A and MYC,
and inhibitors include CDKN1A (p21), SMAD3, TGFB
members, and CDKN2B (p15/INK4). The up- and down-
regulation of these factors by E2 and/or EGFR are
presented in Additional file 8: Table S3. These data
clearly show that there is a general up regulation of
activating factors, and a down regulation of inhibitors
of CyclinD/CdK4/6 by E2. This results in activation of
E2F mediated transcription which is exemplified by
increased transcription of E2F regulated genes [45] such
as CCNA1, CCND1, CCNE2, TK1, PCNA, DHFR, EZH2,
and CDC6 (Additional file 8: Table S3). At the same time,
pro-apoptosis factors (SGPL1, BIK, BMF, APAF1) are
down regulated and anti-apoptotic factors (FAIM3, BCL2,
IER3, HSPB) are upregulated, which contributes to cell
proliferation and survival.
Interestingly, also a number of oncogenes is up regulated
by E2 (MERTK, RET and its ligand ARTN), and several
(putative) tumor suppressor genes are down regulated by
E2 (BLNK, LATS2, RPRM) that are not, or less, regulated
by EGF (Additional file 8: Table S3). Many of these
E2-induced changes in gene expression could be inhibited
with TAM (average inhibition >50%).
On the other hand, EGF-induced signalling relies more
on activation of the RAS/RAF/MEK/MAPK/ELK1 and
PI3K/Akt pathways because phosphorylation of MAPK1/3
and Akt were greatly increased after EGF stimulation of
MCF7/EGFR cells (Figure 1, 5A). Consistent with this
activation, transcription of FOS, EGR1 and JUNB [46-48]
was increased by EGF (Additional file 8: Table S3),
and also up regulation of RELB, GADD45A, ETV5,
ANGPTL4, and down regulation of TOB1 and PDCD4
Figure 6 Differentially expressed genes by E2 and EGF compared to controls and effect of TAM. (A). Number of genes significantly up- or
down-regulated (>1.5×) in MCF7-EGFR cells 6 hr after treatment with E2 (10 nM), EGF (100 ng/ml) or E2 + EGF, with and without 10 μM TAM, compared
to controls as determined by microarray gene expression analysis. (B) The percentage inhibition by TAM for genes >1.5× fold up regulated by exposure
to E2 or EGF. (C) The percentage inhibition by TAM for genes >1.5× fold dow nregulated by exposure to E2 or EGF. Also shown is the inhibition by TAM
of the subsets of E2 or EGF regulated genes that are also regulated by E2 or EGF under the condition of combined exposure to E2 + EGF.
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[49] was observed. Moreover, further increase of JUN/FOS
signalling may occur through cooperation with Smad3
[50] because expression of this factor is also increasedseveral fold as is the upstream regulator of Smad
signalling, TGFBR2 and its ligand TGFB2.
Because the results so far had indicated that EGFR-driven
proliferation may be dependent on the PI3K/Akt pathway
Figure 7 Overlap of E2 and EGF regulated genes. Overlap of genes significantly up- (A) or down-regulated (B) (>1.5×) in MCF7-EGFR cells
6 hr after treatment with E2 (10 nM), EGF (100 ng/ml) or E2 + EGF as determined microarray gene expression analysis.
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investigated PI3K/Akt regulated gene expression. This may
be accomplished via the transcription factors, CREB and
NF-κB [51,52]. Indeed, several CREB target genes [53]
including oncogenes involved in RAS and JUN activation
(CRKL) and inhibition of CDKNB1/p27 Kip1 and p53
activity (MLF1), an anti-apoptotic protein (MCL1), and a
membrane receptor signal regulator (GEM) were increased
after EGF stimulation.
Another pathway that is activated after EGF stimula-
tion is STAT3 mediated signalling. Stat3 can be activated
through EGFR signalling [54], but signalling through this
pathway may also be increased because expression of
both this transcription factor itself and its upstream
activator, IL20 are increased after EGF stimulation
(Additional file 8: Table S3). In addition, the receptor
components IL6R, OSMR, GP130 and the ligand LIF
are also increased which may lead to STAT3 activation
through JAK2 [55].
Also after EGF stimulation (similar to E2 stimulation),
there is a down regulation of pro-apoptosis factors
(SGPL1, BIK, BMF, APAF1) and a tumor suppressor
(BLNK), and up regulation of anti-apoptotic factors
(FAIM3, HSPB), which may contribute to cell proliferation
and survival.
Discussion
Resistance to endocrine therapy in breast cancer remains
a major problem in the clinic. The mechanism behind this
resistance is complex and it is still unclear whether
tamoxifen resistance is based on 1) decreased transcrip-
tion inhibition and consequent proliferation inhibition, 2)
decreased proliferation inhibition via non-classical
genomic or non-genomic actions of the ERα, or 3)
ERα-independent mechanisms. Here we studied the
role of EGFR signalling in this process, using estrogen
responsive MCF7 cells that have increased expression of
wild type EGFR. We showed that EGF-driven signalling inthese cells is sufficient to maintain ERα-independent cell
proliferation.
We generated a MCF7 cell line with ectopic expression
of EGFR, which allowed the unbiased analysis of the inter-
action of EGFR and ERα signalling. In contrast, in many
studies on the mechanism of tamoxifen resistance, MCF7
cells are used that already have an increased expression or
constitutive activation of EGFR and/or downstream MAPK
or Akt activation due to long term culture in the presence
of tamoxifen [9,10,22]. This prohibits the investigation of
the intrinsic effect of EGFR signalling on the antagonistic
activity of tamoxifen in cells that, in the absence of EGF,
respond similarly as the parental MCF7 cells. With respect
to ERα expression, this was similar in our MCF7-EGFR and
parent MCF7 cells, and resembles tamoxifen resistant ERα
positive human tumours that express ERα at normal levels
[56,57]. Therefore, our MCF7-EGFR cell line represents an
important tool to study the mechanisms of tamoxifen
resistance in a more clinically relevant model.
Ectopic expression of human EGFR in MCF7 cells
induced cell proliferation upon stimulation with EGF,
which was ERα-independent, since ERα knock down did
not affect EGF induced proliferation. In agreement with
this, EGF-induced proliferation was not blocked by
tamoxifen or fulvestrant. Therefore, increased EGFR
expression in ERα positive breast cancers may be a sole
important determinant for prediction of anti-estrogen
resistance. Although our data are consistent with litera-
ture data showing tamoxifen, and also (partly) fulvestrant
resistance upon increased EGFR expression in breast
cancer cells, typically these studies involved human breast
cancer cell lines that were long term cultured in the pres-
ence of these antagonists [9,10,22]. It cannot be excluded
that additional changes in other cellular signalling path-
ways parallel or downstream of the EGFR may be mutated
in these models as well. It is relevant to note that while
EGF-induced cell proliferation in MCF7-EGFR cells was
ERα independent and tamoxifen insensitive, the majority
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cells remained sensitive to tamoxifen after EGF stimulation.
These data clearly indicate that during E2 and EGF
co-exposure, cell proliferation and E2-induced transcrip-
tion are controlled by different signalling pathways.
The parental MCF7 and MCF7-EGFR cells showed a
small increase in MAPK1/3 activation after E2 stimulation
which seems consistent with the results of Migliaccio
et al. [58] who observed a 2–3 fold MAPK1/3 activation in
MCF7 cells several minutes after estradiol exposure by
measuring radiolabelled phosphate incorporation in a
MAPK substrate. However, the increase MAPK1/3 activa-
tion by EGF in our MCF7 and MCF7-EGFR cells (5 and
35 fold respectively) is much bigger than the activation by
estradiol (1.5 and 2 fold).
In tamoxifen resistant breast tumour cells an agonistic
effect was observed by tamoxifen both at the level of
ERα-mediated transcription and cell proliferation [9,33].
It has been suggested that these effects of tamoxifen
depend on the phosphorylation of ERα by MAPK1/3 [9,33].
However, not all groups find agonistic effects of tamoxifen
on transcription and/or proliferation after increased
MAPK activation and ERα serine 118 phosphorylation
[34]. Similarly, in our MCF7-EGFR model also no agonistic
effects of tamoxifen were observed on proliferation and
transcription. This is not surprising as the proliferation of
MCF7-EGFR cells after EGF stimulation is already high,
and any possible additional agonistic effects of tamoxifen
may therefore not become manifest. However, it may also
be the result of other cell types being used in the previous
studies compared to our present cell lines. The lack of an
agonistic effect of tamoxifen on transcription after EGFR
activation actually suggests that no agonistic effects of
tamoxifen are induced in our MCF7-EGFR cells by
enhanced EGFR signalling.
EGFR activation in MCF7-EGFR cells caused strong
downstream activation of both the MAPK and Akt
signalling cascades. Using specific inhibitors we demon-
strated that the MEK/MAPK pathway is not dominant
in EGFR-driven proliferation. Recently, using insertion
mutagenesis in an estrogen-dependent breast carcinoma
cell line, a panel of 7 candidate breast cancer anti-estrogen
resistant (BCAR) genes were identified that directly
underlie estrogen independence leading to tamoxifen
resistance, including both EGFR, AKT1, and AKT2 [59].
Importantly, the mRNA levels of these latter candidates in
breast cancer material were significantly correlated with
progression or metastasis free survival [60]. These data
support our findings about the importance of the
PI3K/Akt in the EGFR signalling leading to estrogen
independent proliferation and tamoxifen insensitivity. The
remaining question is which of the downstream targets of
AKT are ultimately responsible for EGF- induced prolifer-
ation in MCF7-EGFR cells. One of the candidates may bec-Jun NH2- terminal kinase (JNK), which can regulate
activator protein (AP)-1 transcription of e.g. cyclin D1 and
other proliferation and survival genes. This hypothesis is
strengthened e.g. by the data of Johnston et al., showing
increased JNK activity and AP-1 DNA-binding in tumours
of resistant patients [61]. Our transcriptomic data are in
agreement with this, but also show activation of other cell
survival and proliferation signalling pathways by EGF,
such as Smad3 and Stat3 signalling, and most likely each
of these contribute to overall cell growth induced by
EGFR activation in MCF7/EGFR cells.
Conclusions
In conclusion, in this paper we have shown that ectopic
expression of EGFR creates an enhanced EGFR signal-
ling that can take over proliferation signalling when
E2-driven proliferation is inhibited by anti-estrogen
therapy. This EGFR-driven proliferation may be dependent
on the PI3K/Akt pathway and to a lesser extent on the
MEK/MAPK pathway.
To overcome anti-estrogen insensitivity induced by this
EGFR signalling, treatment with inhibitors of the EGFR-
PI3K/Akt signalling pathway is indicated. However, our
model shows that EGFR over expressing cells may still
be estrogen sensitive after such treatment. Therefore,
EGFR-PI3K/Akt pathway inhibitors should preferentially
be combined with anti- estrogen treatment.
Additional files
Additional file 1: Figure S1. EGFR over expression induces tamoxifen
resistance as measured by an alternative cell proliferation assay. MCF7-EGFR
cells were estrogen starved 48 hours prior to a 5 day proliferation period in
the absence or presence of 0.1 nM E2 with or without EGF (100 ng/mL) and
a concentration series of TAM. Afterwards, cells were treated and stained
with Hoechst 33258 as described in the Methods section. Data represent
the average ± SEM (n = 3).
Additional file 2: Figure S2. EGF does not downregulate ERα. After
48 hours estrogen starvation, MCF7-wt and MCF7-EGFR cells were
exposed to 100 ng/mL EGF at day 1 and 3, and EGFR and ERα were
analysed on western blots after 2 and 5 days. The ratios of EGFR and
ERα over tubulin are indicated below the blots.
Additional file 3: Figure S3. Ectopic EGFR expression does not induce
tamoxifen resistance on the transcriptional level. Parental MCF7 (A) and
MCF7-EGFR (B) cells were transiently transfected with an ERE-tk- luciferase
construct and estrogen starved for 48 hours before stimulation with
either E2 (0.1 nM) or EGF (100 ng/mL), with or without TAM (100 nM),
or with E2, EGF and TAM, for 12 hours. The normalised luminescence
intensity is shown.
Additional file 4: Figure S4. EGF stimulation of MCF7-EGFR cells
induces only little ERE-dependent transcription that is not enhanced
by TAM. Parental MCF7 (A) and MCF7-EGFR (B) cells were transiently
transfected with an ERE-tk- luciferase construct and estrogen starved for
48 hours before stimulation with either E2 (0.1 nM) or EGF (100 ng/mL),
with or without TAM (100 nM), for 2–12 hours. The normalised luminescence
intensity is shown.
Additional file 5: Figure S5. Ectopic EGFR expression does not induce
agonistic effects of tamoxifen. Parental MCF7 and MCF7-EGFR cells were
estrogen starved 48 hours prior to a 5 day proliferation period with a
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http://www.biomedcentral.com/1471-2407/14/283concentration series TAM, with or without 100 ng/mL EGF. Afterwards,
cells were fixed with 50% TCA and stained with sulforhodamin B, which
absorbance was measured at 540 nm. Data represent the average ± SEM
(n = 3).
Additional file 6: Table S1. Agonistic effect of E2 and EGF on gene
expression.
Additional file 7: Table S2. Antagonistic effect of EGF on E2 induced
gene expression.
Additional file 8: Table S3. E2 and EGF induced changes in gene
expression related to cell proliferation.
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